In a notable portfolio move, life sciences investor Perceptive Advisors significantly increased its stake in Revolution Medicines (RVMD) by 104%, bringing its total holdings to 527,600 shares. The reported market value of the position surged from $25.15 million to $98.81 million, now representing a 1.48% portfolio weight for the fund. This estimated $50.38 million trade makes Perceptive a more substantial holder in the late-stage oncology company.
This transaction was disclosed in a 13F filing on August 14, 2026, which reflects trades made during the second quarter ending June 30. During that period, Revolution Medicines was preparing for the potential U.S. commercial launch of its lead drug candidate, daraxonrasib, for pancreatic cancer. The company also received FDA acceptance for the drug's New Drug Application during the quarter, a key regulatory milestone.